GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » EPS (Diluted)

KPC Pharmaceuticals (SHSE:600422) EPS (Diluted) : ¥0.81 (TTM As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals EPS (Diluted)?

KPC Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was ¥0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.81.

KPC Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2025 was ¥0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.81.

KPC Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2025 was ¥0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.83.

During the past 3 years, the average EPS without NRIGrowth Rate was 14.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, KPC Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 243.90% per year. The lowest was -67.30% per year. And the median was 11.75% per year.


KPC Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for KPC Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals EPS (Diluted) Chart

KPC Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.67 0.51 0.71 0.86

KPC Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.13 0.21 0.35 0.12

Competitive Comparison of KPC Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's PE Ratio falls into.


;
;

KPC Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

KPC Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(648.081-0)/753.583
=0.86

KPC Pharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2025 is calculated as

Diluted EPS (Q: Mar. 2025 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(90.482-0)/754.019
=0.12

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KPC Pharmaceuticals  (SHSE:600422) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


KPC Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals Headlines

No Headlines